FOI 4623-Patients treated for Non-Small Cell Lung Cancer

Date: 12 September 2018 to 12 September 2021

Please provide the following information relating to NSCLC[1] patients treated[2] by your Trust in the 3 months, December 2017 to February 2018 inclusive.

If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.

 

Total number treated Stage IIIB/IV NSCLC Patients

If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:

Patients with NSCLC Stage IIIB/IV (Stage 3b/4)[3]

 

   Total number NSCLC  patients

 

   Other (please specify)

 

   Data not held/accessible

 

 

 

 

Total number treated Stage IIIB/IV NSCLC Patients

If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:

Docetaxel (mono or combination therapy )

 

   Total number NSCLC  patients

 

   Other (please specify)

 

   Data not held/accessible

 

Atezolizumab (Tecentriq)

 

   Total number NSCLC  patients

 

   Other (please specify)

 

   Data not held/accessible

 

Nivolumab (Opdivo)

 

   Total number NSCLC  patients

 

   Other (please specify)

 

   Data not held/accessible

 

Pembrolizumab (Keytruda)

 

   Total number NSCLC  patients

 

   Other (please specify)

 

   Data not held/accessible

 

 

 

  • Request ID:
    FOI 4623
  • Category:
    Patient - Activity Data
  • Response:

    Response attached